Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus chemotherapy in relapsed small-cell lung cancer after platinum-based therapy
jRCT2080222970Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab in small cell lung cancer (SCLC) (2 arms), sponsored by Ono Pharmaceutical. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080222970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222970.